Skip to main content

Weekly insulin efsitora alfa 'noninferior' to daily degludec in type 2 diabetes

Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.

Read more

Editor's Choice

Gestational diabetes and future risk of diabetes and CVD

Growing evidence suggests gestational diabetes increases the future risk of type 2 diabetes and cardiovascular disease, but when is the peak time for concern and are there racial and ethnic disparities?

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Maternally inherited diabetes and deafness

  • Free for a limited time
  • Diabetes
  • Case Study

Genetic testing was needed to diagnose mitochondrial disorder MIDD in a woman with diabetes, weight loss and poor glycemic control. Glycated hemoglobin and pancreatic function improved after treatment with a DPP-4 inhibitor.

Type 2 diabetes: translating advances into real-world practice

Many patients are yet to benefit from the advances and approaches now at our disposal for the management of type 2 diabetes. How can the gaps and delays be addressed?

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Using CGM to optimize type 2 diabetes management with non-intensive insulin treatment in primary care

With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report. 

Supported by:
  • Abbott Diabetes Care
Prof. Samuel Seidu
Developed by: Adis
Listen now

Case Studies

Maternally inherited diabetes and deafness

  • Free for a limited time
  • Diabetes
  • Case Study

Genetic testing was needed to diagnose mitochondrial disorder MIDD in a woman with diabetes, weight loss and poor glycemic control. Glycated hemoglobin and pancreatic function improved after treatment with a DPP-4 inhibitor.

Stevens-Johnson syndrome/toxic epidermal necrolysis complicated with fulminant type 1 diabetes

A rare case of fulminant type 1 diabetes induced by SJS/TEN, which had developed in a patient taking carbamazepine and phenytoin. Glucose monitoring should be considered for patients with SJS/TEN.

Accidental use of dulaglutide into the third trimester

The GLP-1 receptor agonist dulaglutide was unintentionally used by a woman with type 2 diabetes until the third trimester of an unplanned and unrecognized pregnancy, but what was the outcome?

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more

Current Reviews

Insulin Delivery Technology for Treatment of Infants with Neonatal Diabetes Mellitus: A Systematic Review

Neonatal diabetes mellitus is a rare disorder of glucose metabolism with onset within the first 6 months of life. The initial treatment is based on insulin infusion. The technologies for diabetes treatment can be very helpful, even if guidelines …

Characteristics and pregnancy outcomes of subtypes of gestational diabetes mellitus based on HOMA-IR and BMI

Gestational diabetes mellitus (GDM) and its impact on adverse pregnancy outcomes have garnered increasing recognition. Certain modifiable risk factors, such as advanced age, obesity, gestational weight gain, and insulin resistance, play a crucial …

The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function

Type 2 Diabetes (T2D) is a chronic disease with increasing incidence and prevalence and serious chronic complications, especially from cardiovascular system. However, other organs can be affected too. Several studies have associated T2D …

Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis

The International Diabetes Federation Atlas reveals that as of 2021, an estimated 537 million individuals are currently afflicted by diabetes mellitus (DM), with projections indicating an increase to 643 million by 2030 and 783 million by 2045.

Episode 10: Disease-modifying therapy for type 1 diabetes

Reducing the burden of type 1 diabetes

Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.

Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.

Prof. Chantal Mathieu
Listen now

CME & eLearning

Videos | Case Scenarios | Infographics (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.

Supported by:
  • Abbott
Developed by: Springer Healthcare IME

Tweetorials | Vodcasts | Infographics (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)

Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.

Supported by:
  • Abbott
Developed by: Springer Healthcare IME

Vodcasts | Case Scenarios (Link opens in a new window)

Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.

This program is not available to users in the UK and US.

Supported by:
  • Novo Nordisk A/S
Developed by: Springer Healthcare IME

Further Reading

Factors Influencing Treatment Preference in Patients with Diabetic Macular Edema: A Study Using Conjoint Analysis

  • Open Access
  • Diabetes
  • ORIGINAL RESEARCH

Diabetes mellitus (DM) refers to a group of metabolic disorders characterized by an increased concentration of glucose in the blood, and individuals living with diabetes have a higher risk of morbidity and mortality when compared with the general …

Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer

Tyrosine kinase inhibitors (TKIs) have emerged as effective options in the treatment of cancer due to the demonstrated altered activation of these receptors during the development of diverse tumors [ 1 ].

Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial

Type 2 diabetes mellitus (T2DM) is a group of metabolic disorders characterized by long-term high blood glucose, which is caused by defects in insulin secretion and/or action [ 1 ]. It has become the third most serious chronic non-communicable …

The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial

Children with type 1 diabetes mellitus are at increased risk of developing diabetic kidney disease (DKD). This may occur either due to acute kidney injury during diabetes onset that later progresses to chronic kidney disease or due to poor …

Related topics